Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-let-7b-5p ABL1 -0.23 0.93895 0.02 0.9921 miRNAWalker2 validate -0.1 0.00372 NA
2 hsa-miR-128-3p ABL1 -0.44 0.78389 0.02 0.9921 MirTarget -0.12 0.00042 NA
3 hsa-miR-30a-5p ANAPC5 0.22 0.93395 -0.16 0.92347 miRNAWalker2 validate -0.2 0 NA
4 hsa-miR-324-5p ATM -0.5 0.53742 0.19 0.86463 miRanda -0.12 0.00155 NA
5 hsa-miR-455-5p ATM -0.14 0.86574 0.19 0.86463 miRanda -0.12 0.00128 NA
6 hsa-miR-590-5p ATM -0.55 0.47274 0.19 0.86463 mirMAP -0.1 0.00142 NA
7 hsa-miR-139-5p BUB1 -0.08 0.92869 -0.31 0.8008 miRanda -0.15 0.00112 NA
8 hsa-miR-199a-5p BUB1 0.16 0.9358 -0.31 0.8008 miRanda -0.22 0 NA
9 hsa-miR-199b-5p BUB1 -0.04 0.97717 -0.31 0.8008 miRanda -0.15 0.0005 NA
10 hsa-miR-139-5p BUB3 -0.08 0.92869 -0.11 0.94592 miRanda -0.17 0 NA
11 hsa-miR-130a-3p CCNA2 0.09 0.9291 -0.31 0.81453 miRNATAP -0.17 0.00109 NA
12 hsa-miR-199a-5p CCNA2 0.16 0.9358 -0.31 0.81453 miRanda -0.27 0 NA
13 hsa-miR-199b-5p CCNA2 -0.04 0.97717 -0.31 0.81453 miRanda -0.16 0.00129 NA
14 hsa-miR-218-5p CCNA2 0.23 0.81021 -0.31 0.81453 MirTarget -0.29 0 NA
15 hsa-miR-29c-3p CCNA2 0.16 0.94272 -0.31 0.81453 MirTarget -0.17 0.00117 NA
16 hsa-miR-34c-5p CCNA2 -0.02 0.95279 -0.31 0.81453 miRanda -0.25 0 NA
17 hsa-miR-133b CCNB1 0.39 0.56076 -0.28 0.85013 miRanda -0.13 0 NA
18 hsa-miR-139-5p CCNB1 -0.08 0.92869 -0.28 0.85013 miRanda -0.18 0.00084 NA
19 hsa-let-7c-5p CCNB2 -0.06 0.9749 -0.2 0.87078 miRNAWalker2 validate -0.19 0 NA
20 hsa-miR-23b-3p CCNB2 -0.11 0.96135 -0.2 0.87078 miRNAWalker2 validate -0.33 0.00011 NA
21 hsa-miR-16-5p CCND1 0.01 0.99448 -0.25 0.89067 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.13 0.00823 23991964; 22922827; 18483394 At the molecular level our results further revealed that cyclin D1 expression was negatively regulated by miR-16;CCND1 has been found to be a target of miR-15a and miR-16-1 through analysis of complementary sequences between microRNAs and CCND1 mRNA; Moreover the transcription of CCND1 is suppressed by miR-15a and miR-16-1 via direct binding to the CCND1 3'-untranslated region 3'-UTR;Truncation in CCND1 mRNA alters miR 16 1 regulation in mantle cell lymphoma; Furthermore we demonstrated that this truncation alters miR-16-1 binding sites and through the use of reporter constructs we were able to show that miR-16-1 regulates CCND1 mRNA expression; This study introduces the role of miR-16-1 in the regulation of CCND1 in MCL
22 hsa-miR-195-5p CCND1 0.34 0.74962 -0.25 0.89067 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.14 0.00272 21350001; 26631043; 25823925 Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer;MiR 195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1; The present study was to evaluate the level of miR-195 and cyclin D1 in CC tissues and cells; We further investigated the molecular mechanisms of miR-195 and cyclin D1 in CC cell lines HeLa and SiHa; Furthermore the expression of miR-195 was inversely proportional to that of cyclin D1 mRNA or protein p = 0.013 p = 0.015 respectively; However the inhibitor of miR-195 promoted the expression of cyclin D1 and cell proliferation; In conclusion our data suggest that miR-195 may have the potential role in treatment of CC patients as well as miR-195 is a novel regulator of invasiveness and tumorigenicity in CC cells by targeting cyclin D1;MicroRNA profiling identifies MiR 195 suppresses osteosarcoma cell metastasis by targeting CCND1; Meanwhile CCND1 was identified as the target gene of miR-195 and further studied; More importantly using real-time PCR we evaluated the expression of miR-195 and CCND1 in osteosarcoma samples from 107 frozen biopsy tissues and 99 formalin- or paraformalin-fixed paraffin-embedded FFPE tissues; Results indicated lowly expressed miR-195 or highly CCND1 correlated with positive overall survival and their expression inversely related to each other; In summary our study suggests miR-195 functions as a tumor metastasis suppressor gene by down-regulating CCND1 and can be used as a potential target in the treatment of osteosarcoma
23 hsa-miR-29c-3p CCND1 0.16 0.94272 -0.25 0.89067 mirMAP -0.14 0.00181 NA
24 hsa-miR-125b-5p CCNE1 0.04 0.98059 -0.28 0.73651 miRNAWalker2 validate -0.15 0.00074 NA
25 hsa-miR-195-5p CCNE1 0.34 0.74962 -0.28 0.73651 miRNAWalker2 validate; MirTarget; miRNATAP -0.18 0.00302 24402230 Furthermore through qPCR and western blot assays we showed that overexpression of miR-195-5p reduced CCNE1 mRNA and protein levels respectively
26 hsa-miR-26a-5p CCNE2 0.01 0.99772 -0.15 0.8473 miRNAWalker2 validate; miRTarBase; miRNATAP -0.36 0.00084 24116110; 21901171 The loss of miR 26a mediated post transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival; The in vitro and in vivo assays showed that overexpression of miR-26a resulted in cell cycle arrest inhibited cell proliferation and decreased tumor growth which was associated with cyclin E2 downregulation;We also show that enforced expression of miR-26a in AML cells is able to inhibit cell cycle progression by downregulating cyclin E2 expression
27 hsa-miR-30a-5p CCNE2 0.22 0.93395 -0.15 0.8473 miRNATAP -0.44 0 NA
28 hsa-miR-34a-5p CCNE2 -0.5 0.74203 -0.15 0.8473 miRNAWalker2 validate; miRTarBase; miRNATAP -0.22 0.00018 NA
29 hsa-miR-34c-5p CCNE2 -0.02 0.95279 -0.15 0.8473 miRNAWalker2 validate; miRTarBase; PITA; miRanda; miRNATAP -0.28 0 NA
30 hsa-let-7a-3p CDC14A -0.22 0.85543 0.02 0.9701 mirMAP -0.15 0.00458 NA
31 hsa-miR-141-3p CDC14A -0.32 0.87774 0.02 0.9701 TargetScan; miRNATAP -0.13 0.00223 NA
32 hsa-miR-324-5p CDC14A -0.5 0.53742 0.02 0.9701 miRanda -0.13 0.00826 NA
33 hsa-miR-338-3p CDC14A 0.49 0.78848 0.02 0.9701 miRanda -0.12 0.00053 NA
34 hsa-miR-576-5p CDC14A -0.51 0.41719 0.02 0.9701 mirMAP -0.13 0.00588 NA
35 hsa-miR-139-5p CDC16 -0.08 0.92869 0.44 0.76333 miRanda -0.11 0.00566 NA
36 hsa-miR-146b-5p CDC16 -0.4 0.83751 0.44 0.76333 miRanda -0.15 0.00069 NA
37 hsa-miR-23b-3p CDC20 -0.11 0.96135 -0.26 0.85563 miRNAWalker2 validate -0.32 0.00074 NA
38 hsa-miR-30a-5p CDC20 0.22 0.93395 -0.26 0.85563 miRNAWalker2 validate -0.33 3.0E-5 NA
39 hsa-miR-125a-5p CDC23 -0 0.99916 0 0.99805 miRanda -0.1 0.00117 NA
40 hsa-miR-34c-5p CDC23 -0.02 0.95279 0 0.99805 miRanda -0.14 0 25064703 In addition the levels of CDC23 an important mediator in mitotic progression were suppressed following miR-34c expression and siRNAs targeting CDC23 mimicked the effect of miR-34c on G2/M arrest
41 hsa-let-7c-5p CDC25A -0.06 0.9749 -0.28 0.78493 MirTarget -0.22 0 25909324 MicroRNA let 7c Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma; The aim of the present study was to determine whether the cell cycle regulator CDC25A is involved in the antitumor effect of let-7c in HCC; The luciferase reporter assay showed that CDC25A was a direct target of let-7c and that let-7c inhibited the expression of CDC25A protein by directly targeting its 3' UTR; In conclusion this study indicates that let-7c suppresses HCC progression possibly by directly targeting the cell cycle regulator CDC25A and indirectly affecting its downstream target molecules
42 hsa-miR-195-5p CDC25A 0.34 0.74962 -0.28 0.78493 MirTarget; miRNATAP -0.19 0.00029 NA
43 hsa-miR-34c-5p CDC25A -0.02 0.95279 -0.28 0.78493 miRNATAP -0.21 7.0E-5 21321636 Ectopic expression of miR-449b and miR-34c resulted in lowered adhesion activities by 28%-34% and in cell cycle arrests with increased cell number of 15.62% and 15.71% in G1 and with decreased cell number of 15.96% and 16.56% in S Cell cycle related proteins CDK6 and CDC25A were down-regulated; The decreases of CDK6 and CDC25A by miR-449b were 39% and 22% respecyively; 49% and 32% by miR-34c respectively
44 hsa-miR-497-5p CDC25A -0.01 0.98915 -0.28 0.78493 MirTarget; miRNATAP -0.25 7.0E-5 NA
45 hsa-miR-497-5p CDC27 -0.01 0.98915 -0.1 0.93883 miRNATAP -0.15 0 NA
46 hsa-miR-26a-5p CDC6 0.01 0.99772 -0.17 0.88968 miRNAWalker2 validate -0.39 0.00054 25100863; 27158389 Here it is demonstrated that miR26a and miR26b inhibit replication licensing and the proliferation migration and invasion of lung cancer cells by targeting CDC6; The current study suggests that miR26a miR26b and CDC6 and factors regulating their expression represent potential cancer diagnostic and prognostic markers as well as anticancer targets;miR 26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression; Bioinformatics analysis revealed Cdc6 was a target gene of miR-26a; dual-luciferase assay and validation assay showed miR-26a could act on the 3'UTR of Cdc6 to regulate Cdc6 expression; These findings suggest that miR-26a may act on the 3'UTR of Cdc6 to regulate Cdc6 expression which then inhibit the proliferation of ovarian cancer cells and induce their apoptosis
47 hsa-miR-199a-5p CDC7 0.16 0.9358 -0.5 0.532 MirTarget; miRanda -0.24 8.0E-5 NA
48 hsa-miR-199b-5p CDC7 -0.04 0.97717 -0.5 0.532 MirTarget; miRanda -0.17 0.00178 NA
49 hsa-miR-34c-5p CDC7 -0.02 0.95279 -0.5 0.532 miRanda -0.18 0.00111 NA
50 hsa-miR-23b-3p CDK2 -0.11 0.96135 -0.01 0.99411 miRNAWalker2 validate -0.17 0.00275 NA
51 hsa-miR-195-5p CDK4 0.34 0.74962 -0.06 0.97429 miRNAWalker2 validate; miRTarBase -0.18 0 NA
52 hsa-miR-34c-5p CDK4 -0.02 0.95279 -0.06 0.97429 miRNAWalker2 validate; miRTarBase -0.11 0.00308 NA
53 hsa-miR-21-5p CDK6 -0.15 0.97024 0.26 0.8515 miRNAWalker2 validate; mirMAP -0.32 5.0E-5 NA
54 hsa-miR-22-3p CDK6 0.06 0.98656 0.26 0.8515 miRNAWalker2 validate -0.27 0.00121 NA
55 hsa-miR-139-5p CDK7 -0.08 0.92869 -0.07 0.95086 miRanda -0.15 0.00011 NA
56 hsa-let-7c-5p CDKN1A -0.06 0.9749 0.1 0.95314 MirTarget -0.15 0.0033 NA
57 hsa-miR-101-3p CDKN1A 0.01 0.99704 0.1 0.95314 MirTarget -0.4 4.0E-5 NA
58 hsa-miR-708-5p CDKN1A -0.03 0.97493 0.1 0.95314 MirTarget -0.14 0.00964 NA
59 hsa-miR-139-5p CDKN1B -0.08 0.92869 -0.15 0.91962 miRanda -0.13 0.00103 NA
60 hsa-miR-342-3p CDKN1B -0.37 0.77314 -0.15 0.91962 miRanda -0.12 0.00143 NA
61 hsa-miR-582-3p CDKN1B -0.23 0.89768 -0.15 0.91962 PITA -0.11 0.00639 NA
62 hsa-miR-107 CDKN1C -0.04 0.98836 0.62 0.38943 miRanda -0.48 0.00088 NA
63 hsa-miR-25-3p CDKN1C -0.46 0.87857 0.62 0.38943 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.48 6.0E-5 NA
64 hsa-miR-335-5p CDKN1C -0.03 0.97338 0.62 0.38943 miRNAWalker2 validate -0.21 0.00911 NA
65 hsa-miR-429 CDKN1C -0.46 0.80624 0.62 0.38943 miRNATAP -0.23 0.00064 NA
66 hsa-miR-590-3p CDKN1C -0.28 0.59127 0.62 0.38943 miRanda -0.33 0 NA
67 hsa-miR-92a-3p CDKN1C 0.03 0.99325 0.62 0.38943 MirTarget; miRNATAP -0.24 0.0066 NA
68 hsa-let-7g-5p CDKN2A -0.2 0.92299 1.38 0.01803 miRNAWalker2 validate; miRTarBase -0.54 0.00297 NA
69 hsa-miR-19a-3p CDKN2B -0.21 0.84464 0.62 0.5094 mirMAP -0.41 0 NA
70 hsa-miR-19b-3p CDKN2B -0.03 0.98666 0.62 0.5094 mirMAP -0.56 0 NA
71 hsa-miR-335-3p CDKN2B -0.24 0.8845 0.62 0.5094 mirMAP -0.5 0 NA
72 hsa-miR-374b-5p CDKN2B -0.29 0.8357 0.62 0.5094 miRNAWalker2 validate -0.57 0 NA
73 hsa-miR-429 CDKN2B -0.46 0.80624 0.62 0.5094 miRanda -0.34 0 NA
74 hsa-miR-450b-5p CDKN2B -0.01 0.98315 0.62 0.5094 mirMAP -0.29 0.00227 NA
75 hsa-miR-501-3p CDKN2B -0.75 0.55276 0.62 0.5094 PITA -0.29 0.00051 NA
76 hsa-miR-501-5p CDKN2B -0.83 0.05827 0.62 0.5094 mirMAP -0.19 0.00497 NA
77 hsa-miR-502-3p CDKN2B -0.48 0.5143 0.62 0.5094 PITA -0.35 0.00035 NA
78 hsa-miR-576-5p CDKN2B -0.51 0.41719 0.62 0.5094 MirTarget -0.37 4.0E-5 NA
79 hsa-miR-671-5p CDKN2B -0.37 0.41121 0.62 0.5094 PITA -0.27 0.00459 NA
80 hsa-miR-7-1-3p CDKN2B -0.46 0.6659 0.62 0.5094 MirTarget -0.32 0.00025 NA
81 hsa-miR-98-5p CDKN2B -0.17 0.8988 0.62 0.5094 miRNAWalker2 validate -0.38 0.00234 NA
82 hsa-miR-139-5p CHEK1 -0.08 0.92869 -0.28 0.78554 miRanda -0.13 0.00213 NA
83 hsa-miR-195-5p CHEK1 0.34 0.74962 -0.28 0.78554 MirTarget; miRNATAP -0.16 0.00025 25840419 MiR 195 suppresses non small cell lung cancer by targeting CHEK1; We discovered that CHEK1 was a direct target of miR-195 which decreased CHEK1 expression in lung cancer cells
84 hsa-miR-497-5p CHEK1 -0.01 0.98915 -0.28 0.78554 MirTarget; miRNATAP -0.21 5.0E-5 24464213 Checkpoint kinase 1 is negatively regulated by miR 497 in hepatocellular carcinoma; In silico analysis showed that CHEK1 was a candidate target of miR-497 which was previously found to be downregulated in HCC by us; To test whether miR-497 could bind to 3'untranslated region 3'UTR of CHEK1 luciferase reporter assay was conducted; The result revealed that miR-497 could bind to the 3'untranslated region 3'UTR of CHEK1 mRNA; Western blot showed that ectopic expression of miR-497 suppressed the CHEK1 expression and inhibition of miR-497 led to significant upregulation of CHEK1; Finally miR-497 expression was measured in the same 30 HCC samples and the correlation between miR-497 and CHEK1 was analyzed; The results indicated that miR-497 was downregulated in HCC and had a significant negative correlation with CHEK1; Taken together these results demonstrated that CHEK1 was negatively regulated by miR-497 and the overexpressed CHEK1 was resulted from the downregulated miR-497 in HCC which provided a potential molecular target for HCC therapy
85 hsa-miR-493-5p CREBBP 0.23 0.73198 -0.07 0.96314 miRNATAP -0.13 0.00036 NA
86 hsa-miR-199a-5p DBF4 0.16 0.9358 -0.13 0.9016 miRanda -0.17 0.00012 NA
87 hsa-miR-30a-5p DBF4 0.22 0.93395 -0.13 0.9016 MirTarget -0.22 0.00031 NA
88 hsa-miR-23b-3p E2F1 -0.11 0.96135 -0.09 0.94114 miRNAWalker2 validate -0.28 0.00275 NA
89 hsa-let-7c-5p E2F2 -0.06 0.9749 -0.41 0.65832 MirTarget -0.27 0 NA
90 hsa-miR-125b-5p E2F2 0.04 0.98059 -0.41 0.65832 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.24 0 22999819 miR 125b regulates the proliferation of glioblastoma stem cells by targeting E2F2; This study demonstrated that miR-125b plays important roles in regulating the proliferation of GSCs by directly targeting E2F2
91 hsa-miR-30c-2-3p E2F2 0.24 0.74693 -0.41 0.65832 MirTarget -0.28 0.00019 NA
92 hsa-miR-365a-3p E2F2 0.08 0.93876 -0.41 0.65832 MirTarget -0.26 0.00097 NA
93 hsa-let-7b-5p E2F3 -0.23 0.93895 0.05 0.96837 miRNAWalker2 validate -0.12 0.0057 NA
94 hsa-miR-92b-3p E2F3 -0.57 0.68932 0.05 0.96837 miRNATAP -0.1 0.00023 NA
95 hsa-miR-23b-3p E2F4 -0.11 0.96135 0.08 0.95952 miRNAWalker2 validate -0.17 0.00092 NA
96 hsa-let-7e-5p E2F5 0.21 0.92234 -0.16 0.86449 MirTarget; miRNATAP -0.27 0.00167 NA
97 hsa-miR-1271-5p E2F5 -0.46 0.09563 -0.16 0.86449 MirTarget -0.15 0.00563 NA
98 hsa-miR-132-3p E2F5 -0.24 0.87175 -0.16 0.86449 MirTarget -0.24 0.00573 27186275 miR 132 targeting E2F5 suppresses cell proliferation invasion migration in ovarian cancer cells; Mechanism investigation revealed that miR-132 inhibited the expression of transcription factor E2F5 by specifically targeting its mRNA 3'UTR; Moreover the expression level of E2F5 was significantly increased in ovarian cancer tissues than in the adjacent normal tissues and its expression was inversely correlated with miR-132 expression in clinical ovarian cancer tissues; Additionally silencing E2F5 was able to inhibit the proliferation colony formation migration and invasion of ovarian cancer cells parallel to the effect of miR-132 overexpression on the ovarian cancer cells; Meanwhile overexpression of E2F5 reversed the inhibition effect mediated by miR-132 overexpression; These results indicate that miR-132 suppresses the cell proliferation invasion migration in ovarian cancer cells by targeting E2F5
99 hsa-miR-142-3p E2F5 -0.15 0.9461 -0.16 0.86449 miRanda -0.17 0.00024 NA
100 hsa-miR-320b E2F5 -0.24 0.85922 -0.16 0.86449 miRanda -0.21 0.00078 NA
101 hsa-miR-34a-5p E2F5 -0.5 0.74203 -0.16 0.86449 miRNAWalker2 validate; MirTarget; miRNATAP -0.24 7.0E-5 26103003 MicroRNA 34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer; FMNL2 and E2F5 were identified as direct targets of miR-34a; Reintroduction of FMNL2 or E2F5 without 3'UTR region reversed the inhibitory effects of miR-34a on cell proliferation and invasion; MiR-34a was down-regulated in CRC cells and inversely correlated with FMNL2 and E2F5 expressions; Our study suggests that miR-34a is an important tumor suppressor of CRC progression by targeting FMNL2 and E2F5 thus providing new insight into the molecular mechanisms underlying CRC progression and establishing a strong potential for the application of miR-34a as a novel therapeutic marker against CRC
102 hsa-miR-34c-5p E2F5 -0.02 0.95279 -0.16 0.86449 MirTarget; PITA; miRanda; miRNATAP -0.15 0.00886 NA
103 hsa-miR-106b-5p EP300 -0.3 0.86929 -0.28 0.85828 miRNATAP -0.13 0.00096 NA
104 hsa-miR-26b-5p EP300 -0.02 0.99038 -0.28 0.85828 miRNAWalker2 validate; miRNATAP -0.12 0.00816 NA
105 hsa-miR-339-5p EP300 -0.3 0.71291 -0.28 0.85828 miRanda -0.11 0.00013 NA
106 hsa-miR-369-3p EP300 0.12 0.8323 -0.28 0.85828 MirTarget; PITA; miRNATAP -0.15 1.0E-5 NA
107 hsa-let-7c-5p ESPL1 -0.06 0.9749 -0.28 0.80065 MirTarget -0.16 2.0E-5 NA
108 hsa-miR-324-3p GADD45B -0.42 0.66153 0.52 0.61353 MirTarget; miRNATAP -0.22 0.00285 NA
109 hsa-miR-590-3p GADD45B -0.28 0.59127 0.52 0.61353 miRanda -0.23 0 NA
110 hsa-miR-132-3p GSK3B -0.24 0.87175 -0.03 0.98417 mirMAP; miRNATAP -0.11 0.00091 NA
111 hsa-miR-146b-3p GSK3B -0.41 0.76252 -0.03 0.98417 miRNATAP -0.12 0 NA
112 hsa-miR-146b-5p GSK3B -0.4 0.83751 -0.03 0.98417 miRanda -0.14 0 NA
113 hsa-miR-155-5p GSK3B -0.41 0.82867 -0.03 0.98417 miRNAWalker2 validate; miRNATAP -0.1 0 NA
114 hsa-miR-212-3p GSK3B -0.02 0.97323 -0.03 0.98417 mirMAP; miRNATAP -0.11 2.0E-5 NA
115 hsa-miR-30a-5p HDAC1 0.22 0.93395 -0.2 0.91427 miRNAWalker2 validate -0.22 1.0E-5 NA
116 hsa-miR-34c-5p HDAC1 -0.02 0.95279 -0.2 0.91427 miRanda; miRNATAP -0.14 1.0E-5 NA
117 hsa-miR-132-3p HDAC2 -0.24 0.87175 -0.09 0.95418 mirMAP -0.17 0.00036 NA
118 hsa-miR-155-5p HDAC2 -0.41 0.82867 -0.09 0.95418 mirMAP -0.11 0.00036 21946536 Mechanistically we found that BRCA1 epigenetically represses miR-155 expression via its association with HDAC2 which deacetylates histones H2A and H3 on the miR-155 promoter
119 hsa-miR-92b-3p HDAC2 -0.57 0.68932 -0.09 0.95418 mirMAP -0.11 0.00023 NA
120 hsa-miR-133b MAD2L1 0.39 0.56076 -0.32 0.80244 miRanda -0.12 0 NA
121 hsa-miR-139-5p MAD2L1 -0.08 0.92869 -0.32 0.80244 miRanda -0.2 9.0E-5 NA
122 hsa-miR-139-5p MCM2 -0.08 0.92869 -0.26 0.86599 miRanda -0.14 0.00136 NA
123 hsa-miR-34c-5p MCM2 -0.02 0.95279 -0.26 0.86599 miRanda -0.13 0.00246 NA
124 hsa-miR-23b-3p MCM4 -0.11 0.96135 -0.38 0.8115 MirTarget -0.3 0.00061 NA
125 hsa-miR-34a-5p MCM4 -0.5 0.74203 -0.38 0.8115 miRNAWalker2 validate -0.19 0.00032 NA
126 hsa-miR-30c-2-3p MCM6 0.24 0.74693 -0.35 0.80832 MirTarget -0.19 5.0E-5 NA
127 hsa-miR-143-3p MDM2 0.37 0.92734 -0.49 0.72349 miRNAWalker2 validate -0.16 0.00124 NA
128 hsa-miR-320b MYC -0.24 0.85922 -0.45 0.81149 miRNAWalker2 validate -0.24 0.00032 26487644 miR 320b suppresses cell proliferation by targeting c Myc in human colorectal cancer cells; Overexpression of miR-320b in CRC cells was statistically correlated with a decrease of cell growth in vitro and in vivo while c-MYC was identified as a target gene of miR-320b in CRC; Furthermore it was found that up-regulation of c-Myc can attenuate the effects induced by miR-320b; Our identification of c-MYC as a target gene of miR-320b provides new insights into the pathophysiology of CRC proliferation and identifies miR-320b as a novel therapeutic target for the treatment of CRC
129 hsa-miR-217 PCNA 0.34 0.761 -0.32 0.85329 miRanda; miRNATAP -0.11 0.00292 25653720 In vitro treatment with miR-217 mimics significantly suppressed the proliferation of MCF-7 cells induced G1 phase arrest and inhibited the expression of cyclin D1; while these effects were significantly reversed by the restoration of DACH1; In MDA-MB-231 cells treatment with miR-217 inhibitors enhanced the cellular proliferation promoted cell cycle progression and upregulated the expression of cyclin D1 which were neutralized by the pre-treatment of siRNA-DACH1; In vivo inhibition of miR-217 significantly suppressed the xenografts growth and downregulated the expression of cyclin D1
130 hsa-miR-30a-5p PCNA 0.22 0.93395 -0.32 0.85329 miRNAWalker2 validate -0.33 1.0E-5 NA
131 hsa-miR-100-5p PLK1 0.02 0.99282 -0.19 0.89035 miRNAWalker2 validate; miRTarBase -0.2 0 23151088; 22246341; 23842624; 25537513; 22120675; 21636267 MicroRNA 100 is a potential molecular marker of non small cell lung cancer and functions as a tumor suppressor by targeting polo like kinase 1; By using microRNA miR target prediction algorithms we identified miR-100 that might potentially bind the 3'-untranslated region of PLK1 transcripts; The purpose of this study was to investigate the roles of miR-100 and its association with PLK1 in NSCLC development; Finally the effects of miR-100 expression on growth apoptosis and cell cycle of NSCLC cells by posttranscriptionally regulating PLK1 expression were determined; Meanwhile miR-100 mimics could significantly inhibit PLK1 mRNA and protein expression and reduce the luciferase activity of a PLK1 3' untranslated region-based reporter construct in A549 cells; Furthermore small interfering RNA siRNA-mediated PLK1 downregulation could mimic the effects of miR-100 mimics while PLK1 overexpression could partially rescue the phenotypical changes of NSCLC cells induced by miR-100 mimics; Our findings indicate that low miR-100 may be a poor prognostic factor for NSCLC patients and functions as a tumor suppressor by posttranscriptionally regulating PLK1 expression;Together these results suggest that low miR-100 expression may be an independent poor prognostic factor and miR-100 can function as a tumor suppressor by targeting PLK1 in human EOCs;In HCC tissues miR-100 expression was inversely correlated with the expression of plk1 protein r = -0.418; P = 0.029; Therefore downregulation of miR-100 was correlated with progressive pathological feature and poor prognosis in HCC patients and miR-100 could function as a tumor suppressor by targeting plk1;Here we show that miR-100 inhibits maintenance and expansion of BrCSCs in basal-like cancer through Polo-like kinase1 Plk1 down-regulation;MiR 100 resensitizes docetaxel resistant human lung adenocarcinoma cells SPC A1 to docetaxel by targeting Plk1; Knock-down of Plk1 which was a direct target of miR-100 yielded similar effects as that of ectopic miR-100 expression; The inverse correlation between miR-100 and Plk1 expression was also detected in nude mice SPC-A1/DTX tumor xenografts and clinical lung adenocarcinoma tissues and was proved to be related with the in vivo response to docetaxel; Thus our results suggested that down-regulation of miR-100 could lead to Plk1 over-expression and eventually to docetaxel chemoresistance of human lung adenocarcinoma;Reduced miR 100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein; Through modulating miR-100 expression using miR-100 inhibitor or mimic in vitro cell growth cycle and apoptosis were tested separately by MTT or flow cytometry and meanwhile Polo-like kinase1 PLK1 mRNA and protein expressions were detected by qRT-PCR and immunoblotting; The expression of PLK1 in 125 cervical tissues was also examined by immunohistochemical staining and the correlation between miR-100 and PLK1 expression in the same tissues was analysed; The modulation of miR-100 expression remarkably influenced cell proliferation cycle and apoptosis as well as the level of PLK1 protein but not mRNA in vitro experiments; PLK1 expression was negatively correlated with miR-100 expression in CIN3 and cervical cancer tissues; The reduced miR-100 expression participates in the development of cervical cancer at least partly through loss of inhibition to target gene PLK1 which probably occurs in a relative late phase of carcinogenesis
132 hsa-let-7b-3p RAD21 -0.29 0.81216 -0.01 0.99451 miRNATAP -0.13 0.00478 NA
133 hsa-miR-126-5p RAD21 0.08 0.95664 -0.01 0.99451 mirMAP -0.13 0.00331 NA
134 hsa-miR-139-5p RAD21 -0.08 0.92869 -0.01 0.99451 miRanda -0.11 0.00235 NA
135 hsa-miR-142-5p RAD21 -0.12 0.92967 -0.01 0.99451 PITA -0.11 0.00062 NA
136 hsa-miR-195-3p RAD21 0.12 0.69192 -0.01 0.99451 MirTarget; miRNATAP -0.11 0.0008 NA
137 hsa-miR-199a-5p RAD21 0.16 0.9358 -0.01 0.99451 miRanda -0.15 6.0E-5 NA
138 hsa-miR-199b-5p RAD21 -0.04 0.97717 -0.01 0.99451 miRanda -0.12 0.00017 NA
139 hsa-miR-299-5p RAD21 -0.32 0.43535 -0.01 0.99451 MirTarget; PITA; miRNATAP -0.13 3.0E-5 NA
140 hsa-miR-320a RAD21 -0.42 0.8402 -0.01 0.99451 MirTarget; PITA; miRanda; miRNATAP -0.12 0.00372 NA
141 hsa-miR-320b RAD21 -0.24 0.85922 -0.01 0.99451 MirTarget; PITA; miRanda; miRNATAP -0.12 0.00106 NA
142 hsa-miR-433-3p RAD21 -0.03 0.90527 -0.01 0.99451 MirTarget -0.1 0.00136 NA
143 hsa-miR-493-5p RAD21 0.23 0.73198 -0.01 0.99451 miRNATAP -0.14 0.00113 NA
144 hsa-miR-126-5p RBL2 0.08 0.95664 -0.07 0.96185 MirTarget -0.1 0.00637 NA
145 hsa-miR-1287-5p RBL2 -0.39 0.64389 -0.07 0.96185 MirTarget -0.11 0.00463 NA
146 hsa-miR-130a-3p SKP1 0.09 0.9291 0.08 0.96422 MirTarget -0.11 0.00019 NA
147 hsa-miR-152-3p SKP1 0.2 0.90976 0.08 0.96422 MirTarget -0.15 0.00237 NA
148 hsa-miR-26a-5p SKP2 0.01 0.99772 -0.32 0.72696 MirTarget -0.35 7.0E-5 NA
149 hsa-miR-30a-5p SKP2 0.22 0.93395 -0.32 0.72696 MirTarget; miRNATAP -0.34 0 NA
150 hsa-miR-30b-5p SKP2 -0.01 0.99462 -0.32 0.72696 MirTarget; miRNATAP -0.12 0.00985 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 MITOTIC CELL CYCLE 54 766 2.784e-62 1.296e-58
2 CELL CYCLE PROCESS 58 1081 2.157e-61 5.019e-58
3 CELL CYCLE 60 1316 4.382e-60 6.796e-57
4 REGULATION OF CELL CYCLE 53 949 2.332e-55 2.713e-52
5 REGULATION OF MITOTIC CELL CYCLE 39 468 4.108e-45 3.823e-42
6 REGULATION OF CELL CYCLE PHASE TRANSITION 35 321 3.123e-44 2.422e-41
7 CELL CYCLE PHASE TRANSITION 32 255 3.316e-42 2.204e-39
8 REGULATION OF CELL CYCLE PROCESS 38 558 1.96e-40 1.14e-37
9 NEGATIVE REGULATION OF CELL CYCLE 35 433 1.511e-39 7.814e-37
10 CELL CYCLE CHECKPOINT 26 194 9.741e-35 4.532e-32
11 NEGATIVE REGULATION OF CELL CYCLE PROCESS 26 214 1.418e-33 5.999e-31
12 MITOTIC CELL CYCLE CHECKPOINT 23 139 6.935e-33 2.689e-30
13 NEGATIVE REGULATION OF MITOTIC CELL CYCLE 25 199 1.256e-32 4.496e-30
14 CELL CYCLE G1 S PHASE TRANSITION 21 111 2.522e-31 7.825e-29
15 G1 S TRANSITION OF MITOTIC CELL CYCLE 21 111 2.522e-31 7.825e-29
16 CELL DIVISION 30 460 1.117e-30 3.248e-28
17 NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION 21 146 1.22e-28 3.338e-26
18 POSITIVE REGULATION OF CELL CYCLE 25 332 6.421e-27 1.66e-24
19 POSITIVE REGULATION OF CELL CYCLE PROCESS 23 247 7.124e-27 1.745e-24
20 REGULATION OF PROTEIN MODIFICATION PROCESS 41 1710 7.774e-26 1.809e-23
21 REGULATION OF TRANSFERASE ACTIVITY 33 946 3.63e-25 8.042e-23
22 REGULATION OF CELL CYCLE ARREST 17 108 6.175e-24 1.306e-21
23 DNA INTEGRITY CHECKPOINT 18 146 2.635e-23 5.331e-21
24 MITOTIC NUCLEAR DIVISION 23 361 4.741e-23 9.192e-21
25 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 32 1087 4.428e-22 8.242e-20
26 POSITIVE REGULATION OF CELL CYCLE ARREST 15 85 5.489e-22 9.822e-20
27 REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 17 147 1.523e-21 2.625e-19
28 ORGANELLE FISSION 24 496 3.042e-21 5.055e-19
29 SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE 15 96 3.878e-21 6.222e-19
30 G1 DNA DAMAGE CHECKPOINT 14 73 4.064e-21 6.304e-19
31 REGULATION OF ORGANELLE ORGANIZATION 32 1178 5.014e-21 7.525e-19
32 NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 15 98 5.388e-21 7.835e-19
33 MITOTIC DNA INTEGRITY CHECKPOINT 15 100 7.431e-21 1.048e-18
34 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 25 616 2.678e-20 3.664e-18
35 REGULATION OF CELL DIVISION 19 272 8.434e-20 1.121e-17
36 REGULATION OF NUCLEAR DIVISION 16 163 3.891e-19 5.029e-17
37 REGULATION OF CELL PROLIFERATION 33 1496 5.64e-19 7.093e-17
38 CHROMOSOME ORGANIZATION 28 1009 1.912e-18 2.341e-16
39 NEGATIVE REGULATION OF TRANSFERASE ACTIVITY 19 351 1.019e-17 1.216e-15
40 SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 14 127 1.474e-17 1.714e-15
41 CELL CYCLE G2 M PHASE TRANSITION 14 138 4.868e-17 5.524e-15
42 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 31 1492 5.694e-17 6.308e-15
43 REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS 17 274 6.852e-17 7.414e-15
44 REGULATION OF PROTEIN CATABOLIC PROCESS 19 393 8.286e-17 8.762e-15
45 CELLULAR RESPONSE TO DNA DAMAGE STIMULUS 23 720 2.295e-16 2.373e-14
46 POSITIVE REGULATION OF CELL PROLIFERATION 24 814 2.643e-16 2.674e-14
47 POSITIVE REGULATION OF PROTEOLYSIS 18 363 3.889e-16 3.85e-14
48 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 27 1135 4.441e-16 4.305e-14
49 REGULATION OF PHOSPHORUS METABOLIC PROCESS 31 1618 5.537e-16 5.152e-14
50 REGULATION OF SISTER CHROMATID SEGREGATION 11 67 5.511e-16 5.152e-14
51 REGULATION OF LIGASE ACTIVITY 13 130 8.454e-16 7.713e-14
52 REGULATION OF CHROMOSOME ORGANIZATION 16 278 2.035e-15 1.821e-13
53 REGULATION OF PROTEOLYSIS 22 711 2.303e-15 2.022e-13
54 POSITIVE REGULATION OF GENE EXPRESSION 31 1733 3.724e-15 3.209e-13
55 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 23 829 4.748e-15 4.017e-13
56 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 17 360 6.427e-15 5.34e-13
57 CELL CYCLE ARREST 13 154 7.916e-15 6.462e-13
58 REGULATION OF CHROMOSOME SEGREGATION 11 85 8.706e-15 6.984e-13
59 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 31 1805 1.142e-14 9.008e-13
60 REGULATION OF KINASE ACTIVITY 22 776 1.386e-14 1.062e-12
61 NEGATIVE REGULATION OF MOLECULAR FUNCTION 25 1079 1.392e-14 1.062e-12
62 POSITIVE REGULATION OF MITOTIC CELL CYCLE 12 123 1.595e-14 1.191e-12
63 POSITIVE REGULATION OF CELL DEATH 20 605 1.613e-14 1.191e-12
64 REGULATION OF CELL DEATH 28 1472 3.041e-14 2.211e-12
65 CHROMOSOME SEGREGATION 15 272 3.169e-14 2.269e-12
66 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 18 470 3.415e-14 2.407e-12
67 REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 11 97 3.927e-14 2.727e-12
68 SISTER CHROMATID SEGREGATION 13 176 4.523e-14 3.095e-12
69 REGULATION OF CATABOLIC PROCESS 21 731 4.882e-14 3.292e-12
70 NUCLEAR CHROMOSOME SEGREGATION 14 228 5.684e-14 3.778e-12
71 REGULATION OF PROTEIN UBIQUITINATION INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS 11 103 7.744e-14 5.075e-12
72 POSITIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS 13 192 1.395e-13 8.894e-12
73 CELLULAR RESPONSE TO STRESS 28 1565 1.395e-13 8.894e-12
74 ANAPHASE PROMOTING COMPLEX DEPENDENT CATABOLIC PROCESS 10 77 1.493e-13 9.39e-12
75 POSITIVE REGULATION OF FIBROBLAST PROLIFERATION 9 53 2.072e-13 1.286e-11
76 RESPONSE TO OXYGEN LEVELS 15 311 2.242e-13 1.373e-11
77 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 19 616 2.835e-13 1.713e-11
78 DNA REPLICATION 13 208 3.907e-13 2.331e-11
79 POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS 14 263 4.037e-13 2.365e-11
80 RESPONSE TO ABIOTIC STIMULUS 23 1024 4.066e-13 2.365e-11
81 POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 8 36 4.694e-13 2.697e-11
82 REGULATION OF CELLULAR PROTEIN LOCALIZATION 18 552 5.255e-13 2.982e-11
83 PROTEIN PHOSPHORYLATION 22 944 7.24e-13 4.059e-11
84 REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 14 280 9.473e-13 5.247e-11
85 INTRACELLULAR SIGNAL TRANSDUCTION 27 1572 1.189e-12 6.511e-11
86 NEGATIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 11 139 2.196e-12 1.168e-10
87 REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 8 43 2.206e-12 1.168e-10
88 POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION 9 68 2.209e-12 1.168e-10
89 POSITIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 12 196 4.322e-12 2.259e-10
90 NEGATIVE REGULATION OF CHROMOSOME SEGREGATION 7 28 5.852e-12 2.992e-10
91 POSITIVE REGULATION OF LIGASE ACTIVITY 10 110 5.824e-12 2.992e-10
92 REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 7 29 7.692e-12 3.808e-10
93 POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 7 29 7.692e-12 3.808e-10
94 DNA REPLICATION INITIATION 7 29 7.692e-12 3.808e-10
95 REGULATION OF FIBROBLAST PROLIFERATION 9 81 1.128e-11 5.524e-10
96 REGULATION OF DNA METABOLIC PROCESS 14 340 1.296e-11 6.28e-10
97 RESPONSE TO LIPID 20 888 1.89e-11 9.067e-10
98 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 27 1784 2.285e-11 1.085e-09
99 NEGATIVE REGULATION OF MITOTIC NUCLEAR DIVISION 7 34 2.614e-11 1.229e-09
100 POSITIVE REGULATION OF CATALYTIC ACTIVITY 25 1518 2.738e-11 1.274e-09
101 NEGATIVE REGULATION OF CELL DIVISION 8 60 3.711e-11 1.709e-09
102 POSITIVE REGULATION OF INTRACELLULAR TRANSPORT 14 370 3.991e-11 1.821e-09
103 PROTEIN UBIQUITINATION INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS 10 134 4.235e-11 1.913e-09
104 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 16 541 5.347e-11 2.369e-09
105 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 16 541 5.347e-11 2.369e-09
106 PEPTIDYL AMINO ACID MODIFICATION 19 841 6.388e-11 2.804e-09
107 NEGATIVE REGULATION OF CELL PROLIFERATION 17 643 6.988e-11 3.039e-09
108 CELLULAR RESPONSE TO UV 8 66 8.19e-11 3.529e-09
109 POSITIVE REGULATION OF CATABOLIC PROCESS 14 395 9.468e-11 4.042e-09
110 DNA METABOLIC PROCESS 18 758 1.005e-10 4.251e-09
111 REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS 10 148 1.138e-10 4.769e-09
112 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 16 573 1.248e-10 5.138e-09
113 PHOSPHORYLATION 22 1228 1.242e-10 5.138e-09
114 REGULATION OF MEMBRANE PERMEABILITY 8 70 1.331e-10 5.433e-09
115 POSITIVE REGULATION OF RESPONSE TO STIMULUS 27 1929 1.367e-10 5.531e-09
116 POSITIVE REGULATION OF MOLECULAR FUNCTION 26 1791 1.561e-10 6.263e-09
117 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 20 1004 1.684e-10 6.697e-09
118 PROTEASOMAL PROTEIN CATABOLIC PROCESS 12 271 1.891e-10 7.456e-09
119 SISTER CHROMATID COHESION 9 111 2.009e-10 7.854e-09
120 NEGATIVE REGULATION OF NUCLEAR DIVISION 7 46 2.515e-10 9.752e-09
121 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 21 1152 2.68e-10 1.031e-08
122 SPINDLE CHECKPOINT 6 25 2.708e-10 1.033e-08
123 POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 15 514 2.804e-10 1.061e-08
124 RESPONSE TO DRUG 14 431 2.971e-10 1.115e-08
125 REGULATION OF INTRACELLULAR TRANSPORT 16 621 4.046e-10 1.506e-08
126 POSITIVE REGULATION OF STEM CELL DIFFERENTIATION 7 50 4.641e-10 1.714e-08
127 REGULATION OF PROTEIN LOCALIZATION 19 950 5.009e-10 1.835e-08
128 RESPONSE TO UV 9 126 6.276e-10 2.264e-08
129 NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 9 126 6.276e-10 2.264e-08
130 REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS 10 181 8.227e-10 2.945e-08
131 PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 18 873 9.734e-10 3.458e-08
132 CELLULAR RESPONSE TO LIGHT STIMULUS 8 91 1.13e-09 3.923e-08
133 NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS 23 1517 1.118e-09 3.923e-08
134 MITOTIC SISTER CHROMATID SEGREGATION 8 91 1.13e-09 3.923e-08
135 MITOCHONDRIAL MEMBRANE ORGANIZATION 8 92 1.234e-09 4.253e-08
136 CELL PROLIFERATION 16 672 1.268e-09 4.338e-08
137 CELLULAR RESPONSE TO RADIATION 9 137 1.324e-09 4.497e-08
138 POSITIVE REGULATION OF CELL COMMUNICATION 23 1532 1.353e-09 4.563e-08
139 REGULATION OF CELL CYCLE G2 M PHASE TRANSITION 7 59 1.546e-09 5.174e-08
140 RESPONSE TO STEROID HORMONE 14 497 1.879e-09 6.247e-08
141 POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 6 34 2.006e-09 6.618e-08
142 RESPONSE TO ORGANIC CYCLIC COMPOUND 18 917 2.121e-09 6.951e-08
143 DNA DEPENDENT DNA REPLICATION 8 99 2.225e-09 7.241e-08
144 POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 8 100 2.412e-09 7.794e-08
145 NEGATIVE REGULATION OF PHOSPHORYLATION 13 422 2.619e-09 8.403e-08
146 NEGATIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS 7 64 2.775e-09 8.845e-08
147 NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS 8 109 4.802e-09 1.52e-07
148 RESPONSE TO ESTROGEN 10 218 4.979e-09 1.565e-07
149 RESPONSE TO ALCOHOL 12 362 5.058e-09 1.58e-07
150 REGULATION OF DNA REPLICATION 9 161 5.512e-09 1.71e-07
151 CELL DEATH 18 1001 8.368e-09 2.578e-07
152 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 9 171 9.345e-09 2.861e-07
153 PROTEIN CATABOLIC PROCESS 14 579 1.31e-08 3.985e-07
154 NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 15 684 1.359e-08 4.107e-07
155 REGULATION OF MICROTUBULE BASED PROCESS 10 243 1.405e-08 4.219e-07
156 RESPONSE TO ENDOGENOUS STIMULUS 21 1450 1.644e-08 4.902e-07
157 REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION 8 128 1.713e-08 5.077e-07
158 ORGAN REGENERATION 7 83 1.759e-08 5.179e-07
159 NEGATIVE REGULATION OF KINASE ACTIVITY 10 250 1.841e-08 5.387e-07
160 RESPONSE TO RADIATION 12 413 2.187e-08 6.359e-07
161 NEGATIVE REGULATION OF GENE EXPRESSION 21 1493 2.733e-08 7.898e-07
162 CELLULAR RESPONSE TO ABIOTIC STIMULUS 10 263 2.974e-08 8.542e-07
163 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 24 1977 3.499e-08 9.987e-07
164 REGULATION OF TRANSCRIPTION INVOLVED IN G1 S TRANSITION OF MITOTIC CELL CYCLE 5 27 3.712e-08 1.053e-06
165 RESPONSE TO OXYGEN CONTAINING COMPOUND 20 1381 3.977e-08 1.121e-06
166 REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 9 207 4.897e-08 1.364e-06
167 NEGATIVE REGULATION OF CHROMOSOME ORGANIZATION 7 96 4.868e-08 1.364e-06
168 DIGESTIVE SYSTEM DEVELOPMENT 8 148 5.335e-08 1.478e-06
169 REGULATION OF BINDING 10 283 5.926e-08 1.632e-06
170 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 17 1008 6.016e-08 1.647e-06
171 REGULATION OF CELLULAR LOCALIZATION 19 1277 6.211e-08 1.69e-06
172 RESPONSE TO HORMONE 16 893 6.951e-08 1.881e-06
173 REPLICATIVE SENESCENCE 4 12 7.063e-08 1.9e-06
174 REGULATION OF MITOCHONDRION ORGANIZATION 9 218 7.635e-08 2.03e-06
175 REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 9 218 7.635e-08 2.03e-06
176 CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND 12 465 8.004e-08 2.116e-06
177 CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES 7 104 8.483e-08 2.23e-06
178 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 17 1036 8.93e-08 2.321e-06
179 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 17 1036 8.93e-08 2.321e-06
180 RHYTHMIC PROCESS 10 298 9.603e-08 2.482e-06
181 RESPONSE TO GROWTH FACTOR 12 475 1.008e-07 2.592e-06
182 REGENERATION 8 161 1.025e-07 2.62e-06
183 REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 8 162 1.075e-07 2.718e-06
184 POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 8 162 1.075e-07 2.718e-06
185 RESPONSE TO INORGANIC SUBSTANCE 12 479 1.104e-07 2.776e-06
186 NEGATIVE REGULATION OF ORGANELLE ORGANIZATION 11 387 1.118e-07 2.798e-06
187 REGULATION OF CELLULAR RESPONSE TO STRESS 14 691 1.179e-07 2.933e-06
188 POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION 8 167 1.359e-07 3.346e-06
189 REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 6 67 1.357e-07 3.346e-06
190 REGULATION OF STEM CELL DIFFERENTIATION 7 113 1.504e-07 3.683e-06
191 PROTEIN SUMOYLATION 7 115 1.696e-07 4.133e-06
192 REGULATION OF CYTOSKELETON ORGANIZATION 12 502 1.83e-07 4.435e-06
193 MITOCHONDRIAL TRANSPORT 8 177 2.125e-07 5.123e-06
194 REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION 8 178 2.219e-07 5.321e-06
195 NEGATIVE REGULATION OF PROTEOLYSIS 10 329 2.404e-07 5.736e-06
196 RESPONSE TO KETONE 8 182 2.63e-07 6.244e-06
197 PROTEIN UBIQUITINATION 13 629 2.83e-07 6.685e-06
198 POSITIVE REGULATION OF DNA METABOLIC PROCESS 8 185 2.98e-07 7.003e-06
199 MEIOTIC CELL CYCLE 8 186 3.105e-07 7.261e-06
200 NEGATIVE REGULATION OF CELL DEATH 15 872 3.229e-07 7.512e-06
201 POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 7 129 3.721e-07 8.614e-06
202 CHROMATIN MODIFICATION 12 539 3.914e-07 9.016e-06
203 CHROMATIN ORGANIZATION 13 663 5.143e-07 1.179e-05
204 NEGATIVE REGULATION OF CATABOLIC PROCESS 8 203 6.037e-07 1.377e-05
205 RESPONSE TO LIGHT STIMULUS 9 280 6.337e-07 1.438e-05
206 MACROMOLECULE CATABOLIC PROCESS 15 926 6.917e-07 1.562e-05
207 POSITIVE REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 5 48 7.431e-07 1.67e-05
208 POSITIVE REGULATION OF TRANSPORT 15 936 7.918e-07 1.771e-05
209 APOPTOTIC SIGNALING PATHWAY 9 289 8.247e-07 1.827e-05
210 REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 7 145 8.217e-07 1.827e-05
211 RESPONSE TO ESTRADIOL 7 146 8.606e-07 1.898e-05
212 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 21 1848 9.957e-07 2.185e-05
213 POSITIVE REGULATION OF CHROMOSOME ORGANIZATION 7 150 1.032e-06 2.255e-05
214 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 8 220 1.107e-06 2.408e-05
215 INTRINSIC APOPTOTIC SIGNALING PATHWAY 7 152 1.128e-06 2.442e-05
216 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS 4 23 1.227e-06 2.631e-05
217 POSITIVE REGULATION OF COLLAGEN METABOLIC PROCESS 4 23 1.227e-06 2.631e-05
218 GLAND DEVELOPMENT 10 395 1.273e-06 2.717e-05
219 NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS 7 156 1.343e-06 2.854e-05
220 REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 6 99 1.394e-06 2.935e-05
221 REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 6 99 1.394e-06 2.935e-05
222 NEGATIVE REGULATION OF DNA REPLICATION 5 55 1.481e-06 3.104e-05
223 PEPTIDYL LYSINE MODIFICATION 9 312 1.555e-06 3.244e-05
224 RESPONSE TO NITROGEN COMPOUND 14 859 1.609e-06 3.342e-05
225 SMAD PROTEIN SIGNAL TRANSDUCTION 5 56 1.622e-06 3.353e-05
226 HISTONE PHOSPHORYLATION 4 25 1.743e-06 3.573e-05
227 POSITIVE REGULATION OF CHROMOSOME SEGREGATION 4 25 1.743e-06 3.573e-05
228 NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 13 740 1.757e-06 3.585e-05
229 GROWTH 10 410 1.779e-06 3.615e-05
230 REPRODUCTION 17 1297 2.082e-06 4.213e-05
231 REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 5 60 2.293e-06 4.619e-05
232 PROTEIN K11 LINKED UBIQUITINATION 4 27 2.406e-06 4.825e-05
233 CELLULAR RESPONSE TO HYDROGEN PEROXIDE 5 61 2.491e-06 4.975e-05
234 RESPONSE TO METAL ION 9 333 2.654e-06 5.277e-05
235 NEGATIVE REGULATION OF DNA METABOLIC PROCESS 6 111 2.724e-06 5.394e-05
236 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 9 337 2.926e-06 5.768e-05
237 REGULATION OF CELL DIFFERENTIATION 18 1492 3.172e-06 6.195e-05
238 NOTCH SIGNALING PATHWAY 6 114 3.182e-06 6.195e-05
239 REGULATION OF PROTEIN ACETYLATION 5 64 3.166e-06 6.195e-05
240 REGULATION OF HEART MORPHOGENESIS 4 29 3.238e-06 6.278e-05
241 NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 6 115 3.348e-06 6.464e-05
242 COVALENT CHROMATIN MODIFICATION 9 345 3.542e-06 6.81e-05
243 PROTEOLYSIS 16 1208 3.875e-06 7.419e-05
244 CELLULAR RESPONSE TO OXIDATIVE STRESS 7 184 4.028e-06 7.681e-05
245 AGING 8 264 4.299e-06 8.165e-05
246 PROTEIN COMPLEX SUBUNIT ORGANIZATION 18 1527 4.396e-06 8.314e-05
247 POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 6 121 4.497e-06 8.472e-05
248 CELLULAR RESPONSE TO LIPID 10 457 4.671e-06 8.763e-05
249 NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 4 32 4.863e-06 9.08e-05
250 EPITHELIUM DEVELOPMENT 14 945 4.879e-06 9.08e-05
251 RESPONSE TO REACTIVE OXYGEN SPECIES 7 191 5.151e-06 9.549e-05
252 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE 5 71 5.304e-06 9.794e-05
253 REGULATION OF APOPTOTIC SIGNALING PATHWAY 9 363 5.35e-06 9.84e-05
254 G2 DNA DAMAGE CHECKPOINT 4 33 5.519e-06 0.0001011
255 RESPONSE TO MINERALOCORTICOID 4 35 7.025e-06 0.0001277
256 RESPONSE TO IRON ION 4 35 7.025e-06 0.0001277
257 ORGAN MORPHOGENESIS 13 841 7.103e-06 0.0001286
258 DNA REPAIR 10 480 7.189e-06 0.0001297
259 REGULATION OF CELLULAR RESPONSE TO HEAT 5 76 7.424e-06 0.000133
260 POSITIVE REGULATION OF CELL DIVISION 6 132 7.43e-06 0.000133
261 REGULATION OF EPITHELIAL CELL PROLIFERATION 8 285 7.537e-06 0.0001344
262 POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 4 36 7.882e-06 0.00014
263 SENSORY ORGAN DEVELOPMENT 10 493 9.078e-06 0.0001605
264 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 15 1142 9.108e-06 0.0001605
265 REGULATION OF MACROPHAGE CYTOKINE PRODUCTION 3 12 9.218e-06 0.0001612
266 POSITIVE REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS 3 12 9.218e-06 0.0001612
267 REGULATION OF CELL GROWTH 9 391 9.722e-06 0.0001694
268 MESENCHYME MORPHOGENESIS 4 38 9.824e-06 0.0001699
269 REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS 4 38 9.824e-06 0.0001699
270 CELLULAR RESPONSE TO NITROGEN COMPOUND 10 505 1.119e-05 0.0001928
271 CELLULAR RESPONSE TO OXYGEN LEVELS 6 143 1.175e-05 0.0002018
272 MITOTIC CELL CYCLE ARREST 3 13 1.195e-05 0.0002045
273 RESPONSE TO TRANSFORMING GROWTH FACTOR BETA 6 144 1.223e-05 0.0002085
274 POSITIVE REGULATION OF CHROMATIN MODIFICATION 5 85 1.286e-05 0.0002184
275 REGULATION OF DNA DEPENDENT DNA REPLICATION 4 41 1.337e-05 0.0002262
276 POSITIVE REGULATION OF DNA REPLICATION 5 86 1.361e-05 0.0002295
277 PEPTIDYL SERINE MODIFICATION 6 148 1.43e-05 0.0002402
278 BETA CATENIN TCF COMPLEX ASSEMBLY 4 43 1.621e-05 0.0002712
279 REGULATION OF CHROMATIN ORGANIZATION 6 152 1.664e-05 0.0002765
280 MEIOTIC CELL CYCLE PROCESS 6 152 1.664e-05 0.0002765
281 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 7 229 1.68e-05 0.0002782
282 TISSUE DEVELOPMENT 17 1518 1.691e-05 0.0002791
283 TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 5 95 2.21e-05 0.0003633
284 CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND 12 799 2.228e-05 0.000365
285 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 12 801 2.283e-05 0.0003728
286 REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS 3 16 2.323e-05 0.0003739
287 REGULATION OF EXIT FROM MITOSIS 3 16 2.323e-05 0.0003739
288 CELLULAR RESPONSE TO ANTIBIOTIC 3 16 2.323e-05 0.0003739
289 DEVELOPMENTAL GROWTH 8 333 2.321e-05 0.0003739
290 RESPONSE TO TOXIC SUBSTANCE 7 241 2.334e-05 0.0003744
291 REGULATION OF CELL MORPHOGENESIS 10 552 2.406e-05 0.0003847
292 PROTEIN POLYUBIQUITINATION 7 243 2.461e-05 0.0003921
293 RESPONSE TO PROGESTERONE 4 50 2.968e-05 0.0004714
294 NEGATIVE REGULATION OF CELL GROWTH 6 170 3.131e-05 0.0004955
295 MICROTUBULE CYTOSKELETON ORGANIZATION 8 348 3.177e-05 0.0005011
296 RESPONSE TO AMMONIUM ION 4 51 3.212e-05 0.0005049
297 POSITIVE REGULATION OF CELL CYCLE G2 M PHASE TRANSITION 3 18 3.367e-05 0.0005257
298 REGULATION OF UBIQUITIN PROTEIN LIGASE ACTIVITY 3 18 3.367e-05 0.0005257
299 INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR 4 53 3.744e-05 0.0005826
300 CELLULAR RESPONSE TO EXTERNAL STIMULUS 7 264 4.173e-05 0.0006473
301 RESPONSE TO HYDROGEN PEROXIDE 5 109 4.288e-05 0.0006628
302 REGULATION OF RESPONSE TO STRESS 16 1468 4.397e-05 0.0006775
303 TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 11 724 4.586e-05 0.0007043
304 EPITHELIAL TO MESENCHYMAL TRANSITION 4 56 4.658e-05 0.000713
305 NEGATIVE REGULATION OF CELL CYCLE ARREST 3 20 4.68e-05 0.000714
306 REGULATION OF PROTEIN IMPORT 6 183 4.728e-05 0.000719
307 REGULATION OF CYTOPLASMIC TRANSPORT 9 481 4.956e-05 0.0007512
308 POSITIVE REGULATION OF KINASE ACTIVITY 9 482 5.037e-05 0.0007609
309 CELLULAR CATABOLIC PROCESS 15 1322 5.057e-05 0.0007615
310 NEGATIVE REGULATION OF CELL DIFFERENTIATION 10 609 5.52e-05 0.0008285
311 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 17 1672 5.805e-05 0.0008686
312 MESENCHYME DEVELOPMENT 6 190 5.827e-05 0.0008689
313 REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 8 381 6.019e-05 0.0008948
314 NEGATIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE 3 22 6.29e-05 0.0009291
315 ENDOCARDIAL CUSHION MORPHOGENESIS 3 22 6.29e-05 0.0009291
316 POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT 7 282 6.329e-05 0.000932
317 EMBRYONIC DIGIT MORPHOGENESIS 4 61 6.531e-05 0.0009586
318 EMBRYO DEVELOPMENT 12 894 6.639e-05 0.0009714
319 RESPONSE TO INCREASED OXYGEN LEVELS 3 23 7.215e-05 0.001049
320 RESPONSE TO HYPEROXIA 3 23 7.215e-05 0.001049
321 REGULATION OF GROWTH 10 633 7.616e-05 0.001104
322 POSITIVE REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 4 64 7.888e-05 0.00114
323 POSITIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 3 24 8.225e-05 0.001178
324 POSITIVE REGULATION OF G1 S TRANSITION OF MITOTIC CELL CYCLE 3 24 8.225e-05 0.001178
325 POSITIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 3 24 8.225e-05 0.001178
326 POSITIVE REGULATION OF BINDING 5 127 8.881e-05 0.001268
327 MICROTUBULE BASED PROCESS 9 522 9.277e-05 0.001319
328 CELLULAR RESPONSE TO TOXIC SUBSTANCE 3 25 9.323e-05 0.001319
329 POSITIVE REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION 3 25 9.323e-05 0.001319
330 PROTEIN TARGETING 8 406 9.372e-05 0.001321
331 POSITIVE REGULATION OF NEURON DEATH 4 67 9.44e-05 0.001323
332 CELL AGING 4 67 9.44e-05 0.001323
333 MACROMOLECULAR COMPLEX ASSEMBLY 15 1398 9.528e-05 0.001331
334 REGULATION OF CELLULAR SENESCENCE 3 26 0.0001051 0.00146
335 RESPONSE TO CORTICOSTERONE 3 26 0.0001051 0.00146
336 MITOTIC SPINDLE ORGANIZATION 4 69 0.0001059 0.001467
337 REGULATION OF PROTEIN TARGETING 7 307 0.0001076 0.001486
338 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 6 213 0.0001094 0.001507
339 REGULATION OF PROTEIN COMPLEX DISASSEMBLY 6 217 0.0001212 0.001663
340 RESPONSE TO ETHANOL 5 136 0.0001227 0.001679
341 CELLULAR RESPONSE TO STEROID HORMONE STIMULUS 6 218 0.0001243 0.001695
342 CIRCADIAN RHYTHM 5 137 0.000127 0.001728
343 REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 3 28 0.0001318 0.001788
344 CELLULAR RESPONSE TO HORMONE STIMULUS 9 552 0.0001415 0.001909
345 TUBE DEVELOPMENT 9 552 0.0001415 0.001909
346 NEGATIVE REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE 3 29 0.0001466 0.00196
347 REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION 3 29 0.0001466 0.00196
348 POSITIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 3 29 0.0001466 0.00196
349 REGULATION OF TRANSPORT 17 1804 0.0001483 0.001977
350 PROTEIN COMPLEX BIOGENESIS 13 1132 0.0001543 0.002046
351 PROTEIN COMPLEX ASSEMBLY 13 1132 0.0001543 0.002046
352 EYE DEVELOPMENT 7 326 0.000156 0.002062
353 REGULATION OF CELL DEVELOPMENT 11 836 0.0001647 0.002171
354 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 16 1656 0.0001823 0.002389
355 RESPONSE TO TRANSITION METAL NANOPARTICLE 5 148 0.0001823 0.002389
356 NEGATIVE REGULATION OF GROWTH 6 236 0.0001913 0.0025
357 HEAD DEVELOPMENT 10 709 0.0001926 0.002511
358 CHROMATIN REMODELING 5 150 0.000194 0.002522
359 SALIVARY GLAND DEVELOPMENT 3 32 0.0001975 0.002553
360 ENDOCARDIAL CUSHION DEVELOPMENT 3 32 0.0001975 0.002553
361 IMMUNE SYSTEM DEVELOPMENT 9 582 0.0002101 0.002708
362 REGULATION OF PROTEIN EXPORT FROM NUCLEUS 3 33 0.0002167 0.002778
363 REGULATION OF CELL AGING 3 33 0.0002167 0.002778
364 REGULATION OF ORGAN MORPHOGENESIS 6 242 0.000219 0.0028
365 CELLULAR RESPONSE TO INORGANIC SUBSTANCE 5 156 0.0002329 0.002968
366 PROTEIN DESTABILIZATION 3 34 0.0002371 0.003006
367 HEART VALVE DEVELOPMENT 3 34 0.0002371 0.003006
368 HEART DEVELOPMENT 8 466 0.0002406 0.003043
369 MITOCHONDRION ORGANIZATION 9 594 0.0002444 0.003082
370 RESPONSE TO OXIDATIVE STRESS 7 352 0.0002493 0.003136
371 RESPONSE TO MONOAMINE 3 35 0.0002586 0.003244
372 TISSUE REMODELING 4 87 0.0002599 0.003251
373 POSITIVE REGULATION OF CELL DEVELOPMENT 8 472 0.0002623 0.003272
374 MEIOSIS I 4 88 0.0002715 0.003369
375 OVULATION CYCLE PROCESS 4 88 0.0002715 0.003369
376 POSITIVE REGULATION OF PROTEIN ACETYLATION 3 36 0.0002814 0.003473
377 HEAD MORPHOGENESIS 3 36 0.0002814 0.003473
378 MESONEPHROS DEVELOPMENT 4 90 0.0002959 0.003643
379 REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION 3 37 0.0003055 0.00375
380 POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 6 258 0.0003088 0.003772
381 MEMBRANE ORGANIZATION 11 899 0.0003083 0.003772
382 RESPONSE TO CARBOHYDRATE 5 168 0.0003279 0.003994
383 REGULATION OF DNA BINDING 4 93 0.0003355 0.004076
384 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 14 1395 0.0003383 0.004099
385 NEGATIVE REGULATION OF PROTEIN COMPLEX DISASSEMBLY 5 170 0.0003463 0.004185
386 NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS 7 372 0.0003482 0.004198
387 REGULATION OF DNA BIOSYNTHETIC PROCESS 4 94 0.0003494 0.004201
388 CELLULAR RESPONSE TO NUTRIENT 3 39 0.0003575 0.004287
389 CELLULAR MACROMOLECULE LOCALIZATION 13 1234 0.0003584 0.004287
390 EPITHELIAL CELL DIFFERENTIATION 8 495 0.0003608 0.004304
391 REGULATION OF CELL SIZE 5 172 0.0003654 0.004348
392 RESPONSE TO CADMIUM ION 3 40 0.0003855 0.004576
393 CATABOLIC PROCESS 16 1773 0.0003955 0.004683
394 RESPONSE TO CORTICOSTEROID 5 176 0.000406 0.004794
395 HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION 4 98 0.0004095 0.0048
396 POSITIVE REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS 4 98 0.0004095 0.0048
397 RESPONSE TO VITAMIN 4 98 0.0004095 0.0048
398 CELL DEVELOPMENT 14 1426 0.0004227 0.004942
399 NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 4 102 0.0004767 0.005559
400 BODY MORPHOGENESIS 3 44 0.0005115 0.00595
401 POSITIVE REGULATION OF PROTEIN IMPORT 4 104 0.000513 0.005953
402 ODONTOGENESIS 4 105 0.0005319 0.006157
403 INTERSPECIES INTERACTION BETWEEN ORGANISMS 9 662 0.0005387 0.006204
404 SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM 9 662 0.0005387 0.006204
405 EXOCRINE SYSTEM DEVELOPMENT 3 45 0.0005467 0.00628
406 CELLULAR RESPONSE TO EXTRACELLULAR STIMULUS 5 188 0.0005483 0.006284
407 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 6 289 0.0005634 0.00644
408 RESPONSE TO PEPTIDE 7 404 0.0005699 0.0065
409 STEM CELL DIFFERENTIATION 5 190 0.0005753 0.006529
410 TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 5 190 0.0005753 0.006529
411 RESPONSE TO COCAINE 3 46 0.0005833 0.006604
412 RESPONSE TO NUTRIENT 5 191 0.0005892 0.006654
413 MEMBRANE DISASSEMBLY 3 47 0.0006215 0.006952
414 RESPONSE TO ANTIBIOTIC 3 47 0.0006215 0.006952
415 NUCLEAR ENVELOPE DISASSEMBLY 3 47 0.0006215 0.006952
416 POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS 3 47 0.0006215 0.006952
417 POSITIVE REGULATION OF CELL DIFFERENTIATION 10 823 0.0006262 0.006987
418 HOMOLOGOUS CHROMOSOME SEGREGATION 3 48 0.0006612 0.007361
419 REGULATION OF MITOTIC SPINDLE CHECKPOINT 2 11 0.0006694 0.007381
420 POSITIVE REGULATION OF RECEPTOR BIOSYNTHETIC PROCESS 2 11 0.0006694 0.007381
421 NEGATIVE REGULATION OF CELLULAR SENESCENCE 2 11 0.0006694 0.007381
422 REGULATION OF MITOTIC CELL CYCLE SPINDLE ASSEMBLY CHECKPOINT 2 11 0.0006694 0.007381
423 ESTABLISHMENT OF LOCALIZATION IN CELL 15 1676 0.0006787 0.007466
424 OVULATION CYCLE 4 113 0.0007014 0.007697
425 LYMPHOCYTE HOMEOSTASIS 3 50 0.0007455 0.008143
426 FACE DEVELOPMENT 3 50 0.0007455 0.008143
427 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 8 554 0.000757 0.008249
428 POSITIVE REGULATION OF MITOTIC NUCLEAR DIVISION 3 51 0.0007901 0.00859
429 POSITIVE REGULATION OF DNA DEPENDENT DNA REPLICATION 2 12 0.0008014 0.008693
430 IN UTERO EMBRYONIC DEVELOPMENT 6 311 0.0008262 0.00894
431 REGULATION OF CYTOKINE PRODUCTION 8 563 0.0008404 0.009072
432 LYMPHOCYTE DIFFERENTIATION 5 209 0.000884 0.009521
433 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 11 1021 0.0008933 0.009599
434 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 13 1360 0.0008968 0.009615
435 NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 4 121 0.000906 0.009668
436 REGULATION OF B CELL ACTIVATION 4 121 0.000906 0.009668
437 POSITIVE REGULATION OF PROTEIN SECRETION 5 211 0.0009224 0.009822
438 NEGATIVE REGULATION OF CELL COMMUNICATION 12 1192 0.0009263 0.009841
439 POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 2 13 0.000945 0.009859
440 RESPONSE TO ACID CHEMICAL 6 319 0.0009422 0.009859
441 PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 2 13 0.000945 0.009859
442 EYELID DEVELOPMENT IN CAMERA TYPE EYE 2 13 0.000945 0.009859
443 PROTEIN LOCALIZATION TO CHROMATIN 2 13 0.000945 0.009859
444 MITOTIC G2 DNA DAMAGE CHECKPOINT 2 13 0.000945 0.009859
445 REGULATION OF HISTONE PHOSPHORYLATION 2 13 0.000945 0.009859
446 REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL 3 54 0.000934 0.009859
447 RESPONSE TO EXTRACELLULAR STIMULUS 7 441 0.0009532 0.009922
NumGOOverlapSizeP ValueAdj. P Value
1 CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE REGULATOR ACTIVITY 9 28 3.463e-16 3.217e-13
2 ENZYME BINDING 30 1737 3.228e-14 1.5e-11
3 TRANSCRIPTION FACTOR BINDING 17 524 2.8e-12 8.67e-10
4 PROTEIN KINASE ACTIVITY 18 640 6.243e-12 1.45e-09
5 KINASE BINDING 17 606 2.774e-11 5.154e-09
6 KINASE REGULATOR ACTIVITY 11 186 5.273e-11 6.998e-09
7 PROTEIN COMPLEX BINDING 20 935 4.76e-11 6.998e-09
8 KINASE ACTIVITY 19 842 6.518e-11 7.57e-09
9 MACROMOLECULAR COMPLEX BINDING 23 1399 2.287e-10 2.361e-08
10 CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 5 12 3.795e-10 3.526e-08
11 PROTEIN SERINE THREONINE KINASE ACTIVITY 14 445 4.506e-10 3.805e-08
12 PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 6 30 8.954e-10 6.932e-08
13 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 19 992 1.031e-09 7.365e-08
14 CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 6 34 2.006e-09 1.331e-07
15 NF KAPPAB BINDING 5 30 6.498e-08 4.025e-06
16 CYCLIN BINDING 4 19 5.428e-07 3.152e-05
17 KINASE INHIBITOR ACTIVITY 6 89 7.434e-07 4.062e-05
18 RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING 6 104 1.862e-06 9.608e-05
19 P53 BINDING 5 67 3.978e-06 0.0001848
20 ADENYL NUCLEOTIDE BINDING 18 1514 3.898e-06 0.0001848
21 ENZYME REGULATOR ACTIVITY 14 959 5.776e-06 0.0002555
22 CORE PROMOTER BINDING 6 152 1.664e-05 0.000672
23 NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY 15 1199 1.625e-05 0.000672
24 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING 3 15 1.892e-05 0.0007323
25 CHROMATIN BINDING 9 435 2.264e-05 0.0008415
26 TRANSFORMING GROWTH FACTOR BETA RECEPTOR BINDING 4 50 2.968e-05 0.001061
27 HISTONE DEACETYLASE BINDING 5 105 3.583e-05 0.001233
28 TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING 10 588 4.111e-05 0.001317
29 HISTONE KINASE ACTIVITY 3 19 3.988e-05 0.001317
30 ACTIVATING TRANSCRIPTION FACTOR BINDING 4 57 4.997e-05 0.001497
31 CORE PROMOTER PROXIMAL REGION DNA BINDING 8 371 4.994e-05 0.001497
32 PROTEIN C TERMINUS BINDING 6 186 5.177e-05 0.001503
33 RIBONUCLEOTIDE BINDING 18 1860 6.373e-05 0.001794
34 MOLECULAR FUNCTION REGULATOR 15 1353 6.586e-05 0.0018
35 RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING 10 629 7.226e-05 0.001918
36 SMAD BINDING 4 72 0.000125 0.003169
37 TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING 7 315 0.0001262 0.003169
38 REGULATORY REGION NUCLEIC ACID BINDING 11 818 0.0001361 0.003328
39 STEROID HORMONE RECEPTOR BINDING 4 81 0.0001974 0.004702
40 ANDROGEN RECEPTOR BINDING 3 39 0.0003575 0.007723
41 DOUBLE STRANDED DNA BINDING 10 764 0.0003499 0.007723
42 UBIQUITIN LIKE PROTEIN LIGASE BINDING 6 264 0.0003491 0.007723
43 PROTEIN DOMAIN SPECIFIC BINDING 9 624 0.000351 0.007723
NumGOOverlapSizeP ValueAdj. P Value
1 CHROMOSOME 26 880 9.993e-18 5.836e-15
2 CHROMOSOMAL REGION 16 330 2.961e-14 8.646e-12
3 TRANSCRIPTION FACTOR COMPLEX 15 298 1.205e-13 2.345e-11
4 NUCLEAR CHROMOSOME 18 523 2.11e-13 3.08e-11
5 CHROMATIN 16 441 2.514e-12 2.936e-10
6 TRANSFERASE COMPLEX 18 703 2.939e-11 2.86e-09
7 MICROTUBULE CYTOSKELETON 21 1068 6.65e-11 5.548e-09
8 CYCLIN DEPENDENT PROTEIN KINASE HOLOENZYME COMPLEX 6 31 1.107e-09 8.083e-08
9 CENTROSOME 14 487 1.447e-09 9.391e-08
10 CATALYTIC COMPLEX 19 1038 2.183e-09 1.275e-07
11 SPINDLE 11 289 5.63e-09 2.989e-07
12 CHROMOSOME CENTROMERIC REGION 9 174 1.088e-08 5.294e-07
13 ANAPHASE PROMOTING COMPLEX 5 22 1.228e-08 5.515e-07
14 PROTEIN KINASE COMPLEX 7 90 3.103e-08 1.197e-06
15 CONDENSED CHROMOSOME 9 195 2.926e-08 1.197e-06
16 MICROTUBULE ORGANIZING CENTER 14 623 3.278e-08 1.197e-06
17 CULLIN RING UBIQUITIN LIGASE COMPLEX 8 150 5.922e-08 2.034e-06
18 CYTOSKELETON 23 1967 1.491e-07 4.838e-06
19 CYTOSKELETAL PART 19 1436 3.867e-07 1.129e-05
20 NUCLEAR UBIQUITIN LIGASE COMPLEX 5 42 3.753e-07 1.129e-05
21 CONDENSED NUCLEAR CHROMOSOME 6 85 5.658e-07 1.573e-05
22 CONDENSED CHROMOSOME CENTROMERIC REGION 6 102 1.661e-06 4.39e-05
23 CHROMOSOME TELOMERIC REGION 7 162 1.729e-06 4.39e-05
24 UBIQUITIN LIGASE COMPLEX 8 262 4.065e-06 9.892e-05
25 KINETOCHORE 6 120 4.286e-06 0.0001001
26 SPINDLE POLE 6 126 5.683e-06 0.0001277
27 MCM COMPLEX 3 11 6.931e-06 0.0001499
28 CONDENSED CHROMOSOME OUTER KINETOCHORE 3 12 9.218e-06 0.0001923
29 TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS 7 237 2.096e-05 0.0004221
30 CONDENSED NUCLEAR CHROMOSOME CENTROMERIC REGION 3 18 3.367e-05 0.0006555
31 NUCLEAR CHROMATIN 7 291 7.708e-05 0.001452
32 NUCLEAR CHROMOSOME TELOMERIC REGION 5 132 0.0001066 0.001945
33 TRANSCRIPTIONAL REPRESSOR COMPLEX 4 74 0.0001391 0.002461
34 NUCLEOLUS 11 848 0.0001864 0.003202
35 CYTOPLASMIC VESICLE PART 9 601 0.0002665 0.004446
36 RNA POLYMERASE II TRANSCRIPTION FACTOR COMPLEX 4 101 0.0004592 0.00745

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04110_Cell_cycle 71 128 4.564e-167 8.215e-165
2 hsa04114_Oocyte_meiosis 21 114 4.641e-31 4.177e-29
3 hsa04115_p53_signaling_pathway 14 69 1.718e-21 1.031e-19
4 hsa04350_TGF.beta_signaling_pathway 14 85 4.045e-20 1.82e-18
5 hsa04914_Progesterone.mediated_oocyte_maturation 12 87 2.171e-16 7.815e-15
6 hsa04151_PI3K_AKT_signaling_pathway 17 351 4.235e-15 1.27e-13
7 hsa04390_Hippo_signaling_pathway 13 154 7.916e-15 2.036e-13
8 hsa04120_Ubiquitin_mediated_proteolysis 8 139 3.27e-08 7.359e-07
9 hsa04310_Wnt_signaling_pathway 8 151 6.236e-08 1.247e-06
10 hsa04722_Neurotrophin_signaling_pathway 7 127 3.345e-07 6.022e-06
11 hsa03030_DNA_replication 4 36 7.882e-06 0.000129
12 hsa04012_ErbB_signaling_pathway 5 87 1.441e-05 0.0002161
13 hsa04330_Notch_signaling_pathway 4 47 2.317e-05 0.0003209
14 hsa04520_Adherens_junction 4 73 0.0001319 0.001696
15 hsa04144_Endocytosis 5 203 0.0007757 0.009308
16 hsa04630_Jak.STAT_signaling_pathway 4 155 0.002254 0.02535
17 hsa04010_MAPK_signaling_pathway 5 268 0.002637 0.02792
18 hsa04916_Melanogenesis 3 101 0.005572 0.05572
19 hsa03420_Nucleotide_excision_repair 2 45 0.01115 0.1056
20 hsa04720_Long.term_potentiation 2 70 0.02569 0.2312
21 hsa04660_T_cell_receptor_signaling_pathway 2 108 0.05643 0.4837
22 hsa04380_Osteoclast_differentiation 2 128 0.07591 0.5658
23 hsa04360_Axon_guidance 2 130 0.07797 0.5658
24 hsa04510_Focal_adhesion 2 200 0.1586 1

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1

EMX2OS

 hsa-let-7a-3p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-148a-3p;hsa-miR-148b-3p;hsa-miR-186-5p;hsa-miR-200a-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-324-5p;hsa-miR-331-5p;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-374b-5p;hsa-miR-375;hsa-miR-454-3p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-7-5p 23 TGFB2 Sponge network 1.057 0.31716 0.567 0.30298 0.36
2 MEG3 hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-148a-3p;hsa-miR-148b-3p;hsa-miR-186-5p;hsa-miR-200a-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-429;hsa-miR-590-5p 12 TGFB2 Sponge network 0.433 0.33816 0.567 0.30298 0.282
3

CECR7

 hsa-let-7a-3p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-148a-3p;hsa-miR-148b-3p;hsa-miR-186-5p;hsa-miR-200a-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-331-5p;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-362-5p;hsa-miR-375;hsa-miR-429;hsa-miR-454-3p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p 23 TGFB2 Sponge network 0.551 0.56177 0.567 0.30298 0.267

Quest ID: 2edfb058e20fd8352c7e592edf3e0af4